Adia Nutrition's Groundbreaking Kidney Disease Stem Cell Study Receives IRB Approval, Nears Patient Enrollment
ADIA has more than doubled off its 52-week low of $0.018.
Summary
Adia Nutrition announced that its pivotal clinical study for a proprietary stem cell-based therapy targeting chronic kidney disease (CKD) has received Institutional Review Board (IRB) approval and has been submitted to ClinicalTrials.gov. This critical regulatory and ethical milestone allows the company to proceed with patient recruitment for the study, which will evaluate the safety of its AdiaVita stem cell and exosome approach and track changes in key kidney function and inflammation markers. This progress is particularly important for Adia Nutrition, whose recent 10-K filing highlighted substantial doubt about its ability to continue as a going concern, making advancement in its core product pipeline crucial for its viability. Investors will closely monitor updates on patient enrollment and the eventual release of clinical data, as positive developments in this "groundbreaking" therapy could significantly impact the highly speculative stock.
At the time of this announcement, ADIA was trading at $0.15 on OTC in the Life Sciences sector. The 52-week trading range was $0.02 to $0.28. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: TMX Newsfile.